Original Article
Online First™Open AccessMidostaurin does not prolong cardiac repolarization defined in a thorough electrocardiogram trial in healthy volunteers
Adam del Corral, Catherine Dutreix, Alice Huntsman-Labed, Sebastien Lorenzo and Joel Morganroth, et al.
Online First™, 31 January 2012
Original Article
Online First™Open AccessClinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer
Sandhya Girish, Manish Gupta, Bei Wang, Dan Lu and Ian E. Krop, et al.
Online First™, 24 January 2012
Original Article
Online First™Open AccessExposure–response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection
Jian-Feng Lu, Erik Rasmussen, Beth Y. Karlan, Ignace B. Vergote and Lynn Navale, et al.
Online First™, 31 December 2011
Original Article
Online First™Open AccessA phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors
Sukhmani K. Padda, Yelena Krupitskaya, Laveena Chhatwani, George A. Fisher and Alexander D. Colevas, et al.
Online First™, 10 December 2011
Clinical Trial Report
Online First™Open AccessPhase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors
Yoshitaka Seki, Noboru Yamamoto, Yosuke Tamura, Yasushi Goto and Takashi Shibata, et al.
Online First™, 5 December 2011
Original Article
Online First™Open AccessEvaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib
C. Cauchi, N. Somaiah, P. F. Engstrom, S. Litwin and M. Lopez, et al.
Online First™, 26 November 2011
Original Article
Online First™Open AccessPharmacokinetics, metabolism and excretion of [14C]-lenalidomide following oral administration in healthy male subjects
Nianhang Chen, Lian Wen, Henry Lau, Sekhar Surapaneni and Gondi Kumar
Online First™, 29 October 2011
Original Article
Online First™Open AccessA phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer
L. Q. M. Chow, N. Blais, D. J. Jonker, S. A. Laurie and S. G. Diab, et al.
Online First™, 12 October 2011
Clinical Trial Report
Open AccessA phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors
Suzanne Leijen, Patricia M. M. B. Soetekouw, T. R. Jeffry Evans, Marianne Nicolson and Jan H. M. Schellens, et al.
2011, Volume 68, Number 6, Pages 1619-1628
Original Article
Open AccessA multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma
Ana De Jesus-Acosta, George R. Oliver, Amanda Blackford, Katharine Kinsman and Edna I. Flores, et al.
2012, Volume 69, Number 2, Pages 415-424